Magenta Therapeutics (Magenta Therapeutics) Interest Coverage : No Debt ⁽¹⁾ (As of Jun. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Magenta Therapeutics Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Magenta Therapeutics's Operating Income for the three months ended in Jun. 2023 was $-5.46 Mil. Magenta Therapeutics's Interest Expense for the three months ended in Jun. 2023 was $0.00 Mil. Magenta Therapeutics has no debt. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Magenta Therapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.

(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Magenta Therapeutics's Interest Coverage or its related term are showing as below:

MGTA's Interest Coverage is not ranked ^*
in the Biotechnology industry.
Industry Median: 127.155
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Magenta Therapeutics Interest Coverage Historical Data

The historical data trend for Magenta Therapeutics's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Magenta Therapeutics Interest Coverage Chart

Magenta Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Interest Coverage

Get a 7-Day Free Trial

No Debt

N/A

Magenta Therapeutics Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Interest Coverage	Get a 7-Day Free Trial															N/A	N/A	N/A	No Debt	No Debt

Competitive Comparison of Magenta Therapeutics's Interest Coverage

For the Biotechnology subindustry, Magenta Therapeutics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Magenta Therapeutics's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Magenta Therapeutics's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Magenta Therapeutics's Interest Coverage falls into.

Magenta Therapeutics Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Magenta Therapeutics's Interest Coverage for the fiscal year that ended in Dec. 2022 is calculated as

Here, for the fiscal year that ended in Dec. 2022, Magenta Therapeutics's Interest Expense was $0.00 Mil. Its Operating Income was $-80.90 Mil. And its Long-Term Debt & Capital Lease Obligation was $26.14 Mil.

GuruFocus does not calculate Magenta Therapeutics's interest coverage with the available data.

Magenta Therapeutics's Interest Coverage for the quarter that ended in Jun. 2023 is calculated as

Here, for the three months ended in Jun. 2023, Magenta Therapeutics's Interest Expense was $0.00 Mil. Its Operating Income was $-5.46 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Magenta Therapeutics had no debt ⁽¹⁾.

The higher the ratio, the stronger the company's Financial Strength is.

Magenta Therapeutics (NAS:MGTA) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

Magenta Therapeutics Interest Coverage Related Terms

Thank you for viewing the detailed overview of Magenta Therapeutics's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

Magenta Therapeutics (Magenta Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Magenta Therapeutics Inc (NAS:MGTA) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Technology Square, 5th Floor, Cambridge, MA, USA, 02139

Website

https://www.magentatx.com

Magenta Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy. The pipeline of the company includes MGTA-117, MGTA-145, MGTA-45 and others.

Executives

Peter Evan Harwin	director, 10 percent owner	2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Tomas Kiselak	director, 10 percent owner	2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Fairmount Funds Management Llc	director, 10 percent owner	200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Edward Carr	officer: CHIEF ACCOUNTING OFFICER	1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Ryan Savitz	officer: CHIEF FINANCIAL OFFICER	7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Lei Meng	director	7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Simrat Randhawa	officer: Chief Medical Officer	7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Avidity Partners Management Lp	director	2828 N HARWOOD STREET, SUITE 1220, DALLAS TX 75201
Marino Garcia	director, officer: CEO and President	C/O SYNERGY PHARMACEUTICALS INC., 420 LEXINGTON AVENUE, SUITE 2012, NEW YORK NY 10170
Adam M Veness	officer: See Remarks	C/O DIANTHUS THERAPEUTICS, INC., 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Moulder Leon O Jr	director	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Paula Soteropoulos	director	49 WINONA STREET, PEABODY MA 01960
Jonathan Violin	director	955 CHESTERBROOK BOULEVARD, SUITE 200, CHESTERBROOK PA 19087
Third Rock Ventures Iv, L.p.	10 percent owner	29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Michael Vasconcelles	director	C/O UNUM THERAPEUTICS, 200 CAMBRIDGEPARK DR., STE. 3100, CAMBRIDGE MA 02140